Xyrem(oxybate)
Lumryz, Xyrem, Xywav (oxybate) is a small molecule pharmaceutical. Oxybate was first approved as Xyrem on 2002-07-17. It is used to treat cataplexy in the USA. It has been approved in Europe to treat cataplexy and narcolepsy. It is known to target hydroxycarboxylic acid receptor 1.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Lumryz, Xyrem
CombinationsXywav
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Calcium oxybate
+
Magnesium oxybate
+
Potassium oxybate
+
Sodium oxybate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
XYWAV | Jazz Pharmaceuticals | N-212690 RX | 2020-07-21 | 1 products, RLD, RS |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
cataplexy | — | D002385 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
SODIUM OXYBATE, LUMRYZ, AVADEL CNS | |||
2030-05-01 | ODE-431 | ||
2026-05-01 | NP | ||
CALCIUM OXYBATE / MAGNESIUM OXYBATE / POTASSIUM OXYBATE / SODIUM OXYBATE, XYWAV, JAZZ | |||
2028-08-12 | ODE-369 | ||
2027-07-21 | ODE-361 | ||
2024-08-12 | I-870 | ||
2023-07-21 | NP | ||
SODIUM OXYBATE, XYREM, JAZZ PHARMS | |||
2026-04-26 | PED | ||
2025-10-26 | ODE-231 |
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Sodium Oxybate, Lumryz, Avadel Cns | |||
11583510 | 2042-02-07 | U-3578 | |
10925844 | 2040-02-28 | DP | |
10272062 | 2037-07-21 | DP | |
10736866 | 2037-07-21 | DP | |
10952986 | 2037-07-21 | U-3601 | |
10973795 | 2037-07-21 | DP | |
11000498 | 2037-07-21 | DP | U-3580 |
11052061 | 2037-07-21 | DP | |
11065224 | 2037-07-21 | DP | |
11400065 | 2037-07-21 | U-3579 | |
11504347 | 2037-07-21 | DP | |
11602512 | 2037-07-21 | U-3577 | |
11602513 | 2037-07-21 | U-3576 | |
Calcium Oxybate / Magnesium Oxybate / Potassium Oxybate / Sodium Oxybate, Xywav, Jazz | |||
11426373 | 2037-09-19 | U-3432 | |
8772306 | 2033-03-15 | U-1532, U-3198 | |
9050302 | 2033-03-15 | U-1532 | |
9486426 | 2033-03-15 | U-1532 | |
10213400 | 2033-03-15 | U-2499 | |
10864181 | 2033-03-15 | U-1532, U-3017 | |
11253494 | 2033-03-15 | U-3323, U-3324 | |
8591922 | 2033-01-11 | DP | |
8901173 | 2033-01-11 | DP | |
9132107 | 2033-01-11 | DP | |
10195168 | 2033-01-11 | DP | |
10675258 | 2033-01-11 | U-2938 | |
11554102 | 2033-01-11 | DP | |
Sodium Oxybate, Xyrem, Jazz Pharms | |||
7668730 | 2024-06-16 | U-1110 |
HCPCS
No data
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | OXYBATE |
INN | — |
Description | 4-hydroxybutyric acid is a 4-hydroxy monocarboxylic acid that is butyric acid in which one of the hydrogens at position 4 is replaced by a hydroxy group. It has a role as a general anaesthetic, a GHB receptor agonist, a sedative and a neurotoxin. It is a 4-hydroxy monocarboxylic acid and a hydroxybutyric acid. It is functionally related to a butyric acid. It is a conjugate base of a 4-hydroxybutyrate. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | O=C(O)CCCO |
Identifiers
PDB | — |
CAS-ID | 591-81-1 |
RxCUI | 1546380 |
ChEMBL ID | CHEMBL1342 |
ChEBI ID | 30830 |
PubChem CID | 10413 |
DrugBank | DB01440 |
UNII ID | — |
Target
Agency Approved
No data
Alternate
HCAR1
HCAR1
Organism
Homo sapiens
Gene name
HCAR1
Gene synonyms
GPR104, GPR81, HCA1
NCBI Gene ID
Protein name
hydroxycarboxylic acid receptor 1
Protein synonyms
G protein-coupled receptor 104, G-protein coupled receptor 104, G-protein coupled receptor 81, hydroxy-carboxylic acid receptor 1, lactate receptor 1, T-cell activation G protein-coupled receptor
Uniprot ID
Mouse ortholog
Hcar1 (243270)
hydroxycarboxylic acid receptor 1 (Q8C131)
Variants
Clinical Variant
No data
Financial
Xywav - Jazz Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Xyrem - Jazz Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Oxybate - Jazz Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,151 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lumryz, Xyrem, Xywav
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
697 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more